CAJ | 학술논문

目的：探讨美罗华联合化疗在B细胞非霍奇金淋巴瘤治疗中的临床效果。方法：选取我院自2010年5月～2012年5月收治的56例B细胞非霍奇金淋巴瘤患者随机分为观察组与参考组，各为28例，观察组患者在化疗的基础上同时联合美罗华治疗，参考组患者只进行化疗治疗，比较2组患者的临床治疗效果、不良反应发生情况、患者5年内生存率。结果：观察组患者治疗有效率为92．9％，参考组患者治疗有效率为64．3％，2组数据比较差异显著，P＜0．05，有统计学意义；2组患者治疗中均未出现严重不良反应，P＞0．05，无统计学意义。观察组患者5年内生存率为85．7％，参考组患者5年内生存率为53．6％，2组数据比较有统计学意义，P＜0．05，有统计学意义。结论：给予B细胞非霍奇金淋巴瘤患者美罗华联合化疗治疗能够有效提高患者的治愈率，改善患者预后，同时不良反应发生率较低，安全有效，值得在临床进行推广。
목적：탐토미라화연합화료재B세포비곽기금림파류치료중적림상효과。방법：선취아원자2010년5월～2012년5월수치적56례B세포비곽기금림파류환자수궤분위관찰조여삼고조，각위28례，관찰조환자재화료적기출상동시연합미라화치료，삼고조환자지진행화료치료，비교2조환자적림상치료효과、불량반응발생정황、환자5년내생존솔。결과：관찰조환자치료유효솔위92．9％，삼고조환자치료유효솔위64．3％，2조수거비교차이현저，P＜0．05，유통계학의의；2조환자치료중균미출현엄중불량반응，P＞0．05，무통계학의의。관찰조환자5년내생존솔위85．7％，삼고조환자5년내생존솔위53．6％，2조수거비교유통계학의의，P＜0．05，유통계학의의。결론：급여B세포비곽기금림파류환자미라화연합화료치료능구유효제고환자적치유솔，개선환자예후，동시불량반응발생솔교저，안전유효，치득재림상진행추엄。
Objective:To study the mabthera in combination with chemotherapy in B cell non -hodgkin's lymphoma in clinical effect.Methods:our hospital from May 2010 to May 2012, 56 patients with B cell non-hodgkin's lymphoma were treated randomly divided into observation group and reference group, 28 cases in the observation group of patients in the chemotherapy with mabthera therapy at the same time, on the basis of the reference group of patients for chemotherapy treatment, compared two groups of clinical curative effect and adverse reaction of patients with what is happening,and 5 years survival rate.Results:The observation group of patients treatment effective rate was 92.9%, the reference group of patients treatment effective rate was 64.3%, two groups of data was more significant difference, P <0.05, there was statistical significance;Two groups of treatment of the patients with no serious adverse reaction occurred, P >0 .05 , no statistical significance.Observation group of patients within five years survival rate was 85.7%, the reference group 5 years survival rate was 53.6%, two groups of data comparison was statistically significant, P <0. 05, with statistical significance.Conclusion:B cell non-hodgkin's lymphoma patients'mabthera in combination with chemotherapy could improve the cure rate of patients, improve the prognosis of patients, and a lower incidence of adverse reactions, might be safe and effective, worth in clinical promotion.